Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or a left ventricular assist device (LVAD).

Feature | Heart Failure | Dave Fornell, Editor

New Heart Failure Devices and Drugs to Treat Heart Failure

There are several new tools being added to the clinical armamentarium in the fight against heart failure (HF). These ...

February 21, 2020

Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced care, as show here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. The operator is Nevin Kapur. Photo by Dave Fornell.

Feature | Heart Failure | Dave Fornell, Editor

3 New Approaches to Reduce Heart Failure Readmissions

There is no, single magic bullet in heart failure (HF) to easily reduce readmission rates or easily reverse this complex ...

February 20, 2020

he U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption (IDE) application to start a U.S. early feasibility study (EFS) of its total artificial heart.

News | Heart Failure

Carmat to initiate FDA U.S. Feasibility Study of Total Artificial Heart

February 12, 2020 — The U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption ...

February 12, 2020

Sponsored Content

Blog | Artificial Intelligence

BLOG: AI outperforms human analysis in predicting cardiac outcomes

New research shows superiority of Ultromics’ AI in predicting cardiac-related death As the use of artificial ...

October 10, 2022

Videos | Heart Failure

VIDEO: Developing a Heart Failure Care Team

Interview with James Udelson, M.D., chief of the division of cardiology at Tufts Medical Center, Boston. The hospital ...

February 10, 2020

The BioVentrix Revivent TC transcatheter device anchors that help cinch the heart mucsle using a transcatheter procedure to treat left ventricular remodeling associated with heart failure following a heart attack. BioVentrix Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, announced the extension of its European CE mark approval for the Revivent TC Transcatheter Ventricular Enhancement System for heart failure to May 2024.

News

BioVentrix CE Mark Extended for Less Invasive Heart Failure Ventricular Enhancement

January 22, 2020 – BioVentrix Inc., developer of the first transcatheter device for left ventricular remodeling after a ...

January 22, 2020

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals

Fruit Fly Hearts Show How to Keep Human Cardiac Muscle Young

January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies, a ...

January 09, 2020

Abbott announced U.S. Food and Drug Administration (FDA) approval of a new alternative surgical technique for Abbott's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open heart surgery. The new, less invasive approach is designed to provide surgeons a choice in surgical method for patients receiving the HeartMate 3 Left Ventricular Assist Device (LVAD).

News | Ventricular Assist Devices (VAD)

FDA Approves Less Invasive Surgical Approach for HeartMate 3 Heart Pump

January 7, 2020 — Abbott announced U.S. Food and Drug Administration (FDA) approval of a new alternative surgical ...

January 07, 2020

$The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) from AstraZeneca and granted priority review for dapagliflozin (Farxiga) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).$

News

Dapagliflozin Granted FDA Priority Review for Heart Failure With Reduced Ejection Fraction

January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) ...

January 07, 2020

$Developed by Eko, a digital health company applying artificial intelligence (AI) in heart disease, the algorithm analyzes 15 seconds of ECG data collected from the Eko Duo digital stethoscope. The data can be collected during a physical exam and helps identify reduced left ventricular ejection fraction (LVEF), a measure commonly used to diagnose patients with heart failure.$